Literature DB >> 29235674

Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma.

Satoru Shinriki1, Hirofumi Jono2,3, Manabu Maeshiro1,4, Takuya Nakamura4, Jianying Guo5, Jian-Dong Li6, Mitsuharu Ueda5, Ryoji Yoshida4, Masanori Shinohara4, Hideki Nakayama4, Hirotaka Matsui1, Yukio Ando5.   

Abstract

Oral squamous cell carcinoma (OSCC) has a very poor prognosis because of its highly invasive nature, and the 5-year survival rate has not changed appreciably for the past 30 years. Although cylindromatosis (CYLD), a deubiquitinating enzyme, is thought to be a potent tumour suppressor, its biological and clinical significance in OSCC is largely unknown. This study aimed to clarify the roles of CYLD in OSCC progression. Our immunohistochemical analyses revealed significantly reduced CYLD expression in invasive areas in OSCC tissues, whereas CYLD expression was conserved in normal epithelium and carcinoma in situ. Furthermore, downregulation of CYLD by siRNA led to the acquisition of mesenchymal features and increased migratory and invasive properties in OSCC cells and HaCaT keratinocytes. It is interesting that CYLD knockdown promoted transforming growth factor-β (TGF-β) signalling by inducing stabilization of TGF-β receptor I (ALK5) in a cell autonomous fashion. In addition, the response to exogenous TGF-β stimulation was enhanced by CYLD downregulation. The invasive phenotypes induced by CYLD knockdown were completely blocked by an ALK5 inhibitor. In addition, lower expression of CYLD was significantly associated with the clinical features of deep invasion and poor overall survival, and also with increased phosphorylation of Smad3, which is an indicator of activation of TGF-β signalling in invasive OSCC. These findings suggest that downregulation of CYLD promotes invasion with mesenchymal transition via ALK5 stabilization in OSCC cells.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  ALK5; CYLD; mesenchymal transition, invasion; oral squamous cell carcinoma; transforming growth factor-β

Mesh:

Substances:

Year:  2018        PMID: 29235674     DOI: 10.1002/path.5019

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

Review 1.  The resurrection of RIP kinase 1 as an early cell death checkpoint regulator-a potential target for therapy in the necroptosis era.

Authors:  Eunjin Ju; Kyeong Ah Park; Han-Ming Shen; Gang Min Hur
Journal:  Exp Mol Med       Date:  2022-09-28       Impact factor: 12.153

Review 2.  CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.

Authors:  Zhibin Cui; Hyunseok Kang; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Res       Date:  2020-09-03       Impact factor: 6.333

3.  The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.

Authors:  Athanasios Pseftogas; Konstantinos Xanthopoulos; Theofilos Poutahidis; Chrysanthi Ainali; Dimitra Dafou; Emmanuel Panteris; Joseph G Kern; Xaralabos Varelas; Alexander Hardas; Christos Gonidas; Anastasia Tsingotjidou; Eudoxia Hatzivassiliou; George Mosialos
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

4.  Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.

Authors:  Naoki Suenaga; Mimi Kuramitsu; Kanae Komure; Ayumi Kanemaru; Kanako Takano; Kazuya Ozeki; Yuka Nishimura; Ryoji Yoshida; Hideki Nakayama; Satoru Shinriki; Hideyuki Saito; Hirofumi Jono
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

5.  Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma.

Authors:  Shunsuke Miyake; Toru Miwa; Go Yoneda; Ayumi Kanemaru; Haruki Saito; Ryosei Minoda; Yorihisa Orita; Hideyuki Saito; Hirofumi Jono
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

6.  The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Rin Liu; Satoru Shinriki; Manabu Maeshiro; Mayumi Hirayama; Hirofumi Jono; Ryoji Yoshida; Hideki Nakayama; Hirotaka Matsui
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

7.  CYLD, a mechanosensitive deubiquitinase, regulates TGFβ signaling in load-induced bone formation.

Authors:  Jacqueline Nguyen; Ramin Massoumi; Tamara Alliston
Journal:  Bone       Date:  2019-11-09       Impact factor: 4.398

Review 8.  Ubiquitination and Deubiquitination in Oral Disease.

Authors:  Sachio Tsuchida; Tomohiro Nakayama
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

Review 9.  Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.

Authors:  Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng; Chang Yang; Ya-Nan Pi; Bin-Bin Cui; Wei-Lin Jin
Journal:  Front Cell Dev Biol       Date:  2021-06-09

Review 10.  Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (Review).

Authors:  Xueling Cui; Shumi Shang; Xinran Lv; Jing Zhao; Yan Qi; Zhonghui Liu
Journal:  Mol Med Rep       Date:  2019-04-30       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.